Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1/2 10Phase 3 3Phase 1 2Phase NA 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Ovarian Neoplasms 29Fallopian Tube Neoplasms 15Breast Neoplasms 10Carcinoma, Ovarian Epithelial 6Peritoneal Neoplasms 3Multiple Myeloma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Vaccinia 1Uterine Cervical Neoplasms 1Sarcoma, Kaposi 1Pelvic Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Low Grade Serous Ovarian Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Genital Neoplasms, Female 1Genetic Predisposition to Disease 1Endometrial Neoplasms 1Carcinoma 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

Dexamethasone 169Bortezomib 92Lenalidomide 85daratumumab 44Thalidomide 44pomalidomide 43Melphalan 40Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14isatuximab 12Filgrastim 12ixazomib 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5iberdomide 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × liposomal doxorubicin × Clear all
NCT00097981 2017-04-07

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
225 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT00103506 2015-10-19

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Janssen Research & Development, LLC

Phase 3 Completed
646 enrolled 10 charts
Plasma cell

Multiple Myeloma

NCT00344422 2011-06-10

Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
198 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡